CoChat

Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis

Open access

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Background: Antipsychotic medications are the mainstay of treatment for schizophrenia and are associated with a reduction in psychiatric hospitalization and overall mortality. Some evidence suggest that antipsychotic medications might have a varying effect on the improvement of comorbid substance use disorders (SUDs), with clozapine showing more favorable outcomes. Aim: We systematically reviewed all available evidence on effects of clozapine on the improvement of SUDs other than nicotine. Methods: Electronic searches of MEDLINE, Embase, PsycINFO, and CINHAL were conducted up to March 1, 2022. Studies of any methodological design involving two concepts: (1) clozapine and (2) SUD terms (excluding nicotine) were included. For SUD outcomes with three or more comparative studies with available raw data meta-analysis was performed. SUD outcomes not meeting criteria for meta-analysis were described qualitatively. Risk of bias was examined using “Downs and Black,” and “Q-Coh” instruments. Results: The majority of individuals in the included 31 studies were male and of European ancestry. Abstinence was the most common outcome. Most of the studies were of low-to-moderate quality, and none of the studies met all the quality criteria. Pooled findings from four observational studies in samples of patients with predominantly comorbid alcohol use disorder showed that clozapine treatment is associated with significantly higher odds of remaining abstinent. In addition clozapine was associated with decreased odds of psychiatric hospitalization in all but one observational study. Conclusions: Our systematic review and meta-analysis builds upon previous reviews, and it suggests the association of clozapine treatment with significantly higher odds of remaining abstinent from substance use and decreased likelihood of psychiatric hospitalization, compared with continuing treatment with other antipsychotic medications. Still, the validity of this association needs greater exploration and providing recommendations for the utility of clozapine in individuals without treatment-resistant psychosis and comorbid SUDs would be premature.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/02698811221142575

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. PRISMA flow chart detailing the article selection process.
Figure 1. PRISMA flow chart detailing the article selection process.CC BY-NC · PubMed Central
Figure 2. Forest plot for the association of clozapine treatment with odds of abstinence in comparison with other antipsychotics.
Figure 2. Forest plot for the association of clozapine treatment with odds of abstinence in comparison with other antipsychotics.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 7

  1. Brunette MF, 2011, Schizophr Bull, 37, 297
  2. GBD, 2019, Lancet Psychiatry, 9, 137
  3. Lee ML, 1998, Can J Psychiatry, 43, 855
  4. Page MJ, 2021, BMJ, 372
  5. Seddigh R, 2014, Case Rep Psychiatry, 2014, 845145
  6. Tang SM, 2017, J Can Acad Child Adolesc Psychiatry, 26, 51
  7. Yee MR, 2021, Cureus, 13

Cited by

See all 41

Metadata

Authors
Rafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew, N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C. G.
Affiliations
  • University of British Columbia (CA)
  • University of Toronto (CA)
  • University of Calgary (CA)
Corresponding author
Rafizadeh, Reza
Venue
Journal of Psychopharmacology
Published
2022-12-12
Volume
37
Issue
2
Pages
135-143
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W4311204828
Cited by
41
References
55
Citations by year
2026: 12 · 2025: 16 · 2024: 9 · 2023: 4
FWCI
1.25
Type
journal article
Language
en
Open access
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
National Institute on Drug Abuse (R25DA037756)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
clozapine, substance use disorders, schizophrenia spectrum disorders, alcoholism, abstinence, psychiatric hospitalization, antipsychotic drugs, comorbidities, treatment-resistant psychosis
MeSH terms
Clozapine, Female, Humans, Male, Nicotine, Schizophrenia, Antipsychotic Agents, Substance-Related Disorders, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1177/02698811221142575
The paper
Rafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew, N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C. G. (2023). Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221142575

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.